Drug Patents owned by Impact
1. List of Inrebic drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7528143 | IMPACT | Bi-aryl meta-pyrimidine inhibitors of kinases |
Dec, 2026
(3 years from now) | |
| US7825246 | IMPACT | Bi-aryl meta-pyrimidine inhibitors of kinases |
Dec, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8138199 | IMPACT | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
Jun, 2028
(5 years from now) | |
| US10391094 | IMPACT | Compositions and methods for treating myelofibrosis |
Jun, 2032
(9 years from now) | |
| US11400092 | IMPACT | Methods of treating myeloproliferative disorders |
Sep, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 16, 2026 |
| New Chemical Entity Exclusivity (NCE) | Aug 16, 2024 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis; Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring thiamine levels and administering thiamine or a thiamine equivalent
Dosage: CAPSULE;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic